NRx Pharmaceuticals announces initiation of Phase 2b trial of BriLife vaccine for Covid-19
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
CDSCO to fast-track trials and approval for COVID19 vaccine
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first batch will be shipped to the Gamaleya Center for the quality control
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Subscribe To Our Newsletter & Stay Updated